DS
Therapeutic Areas
Genscript Biotech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Ciltacabtagene autoleucel (Carvykti) | Relapsed/Refractory Multiple Myeloma | Approved / Phase 3 |
| LB1901 | Relapsed/Refractory T-cell Lymphoma | Phase 1 |
| LB2102 | Extensive-Stage Small Cell Lung Cancer | Phase 1 |
| LB1911 | Pancreatic Cancer, Colorectal Cancer | Preclinical / Phase 1 (planned) |